Cutting-edge Cancer Drugs Ambagon Therapeutics is developing small molecule cancer drugs that target oncogenic proteins, presenting an opportunity for collaboration in advancing cancer treatment.
Recent Funding Boost With a recent financing round of $85 million, Ambagon has the resources to drive research and development, making them a potential partner for investment or strategic partnerships.
Expanding Treatment Therapies Ambagon Therapeutics is expanding treatment therapies based on proteins, opening avenues for partnerships in research, development, and commercialization of innovative therapies.
Specialization in Unmet Clinical Needs By addressing major unmet clinical needs beyond oncology, Ambagon's platform approach creates opportunities for collaborations focused on tackling challenging medical conditions.
Strategic Positioning in Biotechnology While navigating the biotechnology landscape, Ambagon Therapeutics' unique focus on stabilizing protein interactions positions them as a potential key player for strategic alliances and exploration of cutting-edge technologies.
138
$10M$50M
381$10M$50M
570$50M$100M
82$10M$50M
123$10M$50M
74$10M$50M
24$10MAmbagon Therapeutics uses 8 technology products and services including Font Awesome, Google Cloud, jQuery, and more. Explore Ambagon Therapeutics's tech stack below.
| Ambagon Therapeutics Email Formats | Percentage |
| FLast@ambagontx.com | 49% |
| First@ambagontx.com | 1% |
| First-Last@ambagontx.com | 1% |
| FLast@ambagontx.com | 49% |
Biotechnology ResearchCalifornia, United States11-50 Employees
Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s platform approach will open opportunities to address major unmet clinical needs beyond oncology.
Company Overview
Media & News
Funding & FinancialsAmbagon Therapeutics has raised a total of $45M of funding over 3 rounds. Their latest funding round was raised on May 27, 2022 in the amount of $45M.
Ambagon Therapeutics's revenue is in the range of $10M
Funding & FinancialsAmbagon Therapeutics has raised a total of $45M of funding over 3 rounds. Their latest funding round was raised on May 27, 2022 in the amount of $45M.
Ambagon Therapeutics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com